Hu Tingting, Xu Yiting, Li Xiaoya, Xiao Yunfeng, Wang Yufei, Bao Yuqian, Ma Xiaojing
Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Department of Radiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
J Clin Endocrinol Metab. 2025 Jan 21;110(2):345-355. doi: 10.1210/clinem/dgae531.
Several cross-sectional studies have reported the association between serum adipocyte fatty acid-binding protein (A-FABP) level and presarcopenia. However, data on the effects of serum A-FABP level and its changes over time on the development and improvement of presarcopenia are scarce.
This study aimed to explore the association of serum A-FABP level with the incidence and improvement of presarcopenia in a community-based cohort, and further investigated the association of changes in serum A-FABP level with the incidence and improvement of presarcopenia.
This longitudinal cohort study included 1496 adults (41.2% men; median age, 58 [53-63] years) in 2013 to 2014 and was followed up to 2015 to 2016. Participants underwent serum A-FABP level measurements at baseline and a follow-up visit. Visceral fat area (VFA) was measured using magnetic resonance imaging. Skeletal muscle mass (SMM) was estimated by bioelectrical impedance analysis and converted to a skeletal muscle index (SMI). Presarcopenia was defined as SMI less than 1 SD of the sex-specific mean for the young reference group.
During an average follow-up period of 2.1 years, baseline serum A-FABP level was positively associated with the incidence of presarcopenia (standardized by weight: risk ratio [RR] 3.22; 95% CI, 1.96-5.38; standardized by VFA: RR 2.11, 95% CI, 1.29-3.51) and negatively associated with the improvement of presarcopenia (standardized by weight: RR 0.66; 95% CI, 0.45-0.97; standardized by VFA: RR 0.71; 95% CI, 0.54-0.94), regardless of whether SMM was standardized by weight or VFA. Moreover, changes in serum A-FABP level provided additional information on the incidence and improvement of presarcopenia, independent of baseline serum A-FABP level (all P < .05).
Baseline serum A-FABP level and its changes were positively associated with the incidence and negatively associated with the improvement of presarcopenia.
多项横断面研究报告了血清脂肪细胞脂肪酸结合蛋白（A-FABP）水平与肌肉减少症前期之间的关联。然而，关于血清A-FABP水平及其随时间的变化对肌肉减少症前期的发生和改善的影响的数据却很少。
本研究旨在探讨基于社区的队列中血清A-FABP水平与肌肉减少症前期的发生率和改善情况之间的关联，并进一步研究血清A-FABP水平的变化与肌肉减少症前期的发生率和改善情况之间的关联。
这项纵向队列研究纳入了2013年至2014年的1496名成年人（男性占41.2%；中位年龄为58[53-63]岁），并随访至2015年至2016年。参与者在基线和随访时进行了血清A-FABP水平测量。使用磁共振成像测量内脏脂肪面积（VFA）。通过生物电阻抗分析估算骨骼肌质量（SMM），并将其转换为骨骼肌指数（SMI）。肌肉减少症前期定义为SMI低于年轻参考组特定性别的平均值1个标准差。
在平均2.1年的随访期内，无论SMM是按体重还是VFA进行标准化，基线血清A-FABP水平与肌肉减少症前期的发生率呈正相关（按体重标准化：风险比[RR]3.22；95%CI，1.96-5.38；按VFA标准化：RR 2.11，95%CI，1.29-3.51），与肌肉减少症前期的改善呈负相关（按体重标准化：RR 0.66；95%CI，0.45-0.97；按VFA标准化：RR 0.71；95%CI，0.54-0.94）。此外，血清A-FABP水平的变化提供了关于肌肉减少症前期发生率和改善情况的额外信息且独立于基线血清A-FABP水平（所有P<.05）。
基线血清A-FABP水平及其变化与肌肉减少症前期的发生率呈正相关，与肌肉减少症前期的改善呈负相关。
